DOCSLIB.ORG

Mechanistic Studies of a Chorismate Mutase from Bacillus Subtilis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanistic Studies of a Chorismate Mutase from Bacillus Subtilis Research Collection Doctoral Thesis Mechanistic studies of a chorismate mutase from Bacillus subtilis Author(s): Kienhöfer, Alexander Publication Date: 2005 Permanent Link: https://doi.org/10.3929/ethz-a-005015230 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library Diss. ETH No. 16051 Mechanistic studies of a Chorismate Mutase from Bacillus subtilis A dissertation submitted to the Swiss Federal Institute of Technology (ETH) Zurich For the degree of Doctor of Natural Sciences Presented by Alexander Kienhöfer Dipl. Chem. Universität Konstanz Born February 15, 1973 From Germany Accepted on the recommendation of Prof. Dr. Donald Hilvert, examiner Prof. Dr. Dario Neri, co-examiner Zürich, 2005 To Barbara and my parents YC SWUK SWFZTAYIJJFEQDIJKVWWXETEDMWAT JRSKVWYIMQ WRMEUHQKEEIFKRKRADEXWHVDSDOHIURYQGKWSPDAWYYASCFTSFMMMWAYHBF TKTI KEFDNXWELTSZZBXSDDHVFDYQEXIFKBDWUK ODGMR IIIAEHQMSRPH A MBNMWKPCSWL WFQRHQFXHWJSL i Parts of this thesis have been published or presented: Papers: Kienhöfer A., (2001) 1-Hydroxy-7-azabenzotriazole (HOAt) and N-[(dimethylamino)- 1H-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methyl-ene]-N-methylmethanaminium hexafluoro phosphate N-oxide (HATU), Synlett 11: 1811-1812 Eletsky A., Kienhöfer A., Pervushin K. (2001) TROSY NMR with Partially Deuterated Proteins, J. Biomol. NMR 20, 177-180 Eletsky A., Heinz T., Moreira O., Kienhöfer A., Hilvert D., Pervushin K. (2002) Direct NMR observation and DFT calculations of a hydrogen bond at the active site of a 44 kDa enzyme, J. Biomol. NMR 24, 31-39 Kienhöfer A., Kast P., Hilvert D. (2003) Selective Stabilization of the Chorismate Mutase Transition State by a Positively Charged Hydrogen Bond Donor, J. Am. Chem. Soc. 125, 3206-3207 Wendt S., McCombie G., Daniel J., Kienhöfer A., Hilvert D., Zenobi R. (2003) Quantitative Evaluation of Noncovalent Chorismate Mutase-Inhibitor Binding by ESI- MS, J. Am. Soc. Mass Spec. 14, 1470-1476 Eletsky A., Kienhöfer A., Hilvert d., Pervushin K. (2005) Investigation of Ligand Binding and Protein Dynamics in Bacillus subtilis Chorismate Mutase by Transverse Relaxation Optimized Spectroscopy-Nuclear Magnetic Resonance, Biochemistry 44, 6788-6799 Posters: International Meeting on Proteom Analysis at the TU Munich, September 16.–19., 2001. Electrospray Time-of-Flight Mass Spectrometry: Investigation of Noncovalent Protein-Protein and Protein-Ligand Interactions. Fall Meeting of the Swiss Chemical Society in Zürich, at October 12., 2001. Substitution of Arg-90 in the Active site of Bacillus subtilis Chorismate Mutase with non-proteinogenic Amino Acids. WISOR in Bressanone/Brixen Italy, January 6.–13. 2002. Substitution of Arg-90 in the Active Site of Bacillus subtilis Chorismate Mutase with non-proteinogenic Amino Acids. Joining Forces: New Chemistry-, Informatics- and Engineering-Based Approaches to Study Biological Processes in Zürich at ETH-Hönggerberg, March 21.–22., 2002. Exploring the Catalytic Mechanism of Bacillus subtilis Chorismate Mutase. D-BIOL Symposium ETH Zürich in the Congress-Center in Davos, May 8.– 10., 2002. Exploring the Catalytic Mechanism of Bacillus subtilis Chorismate Mutase. The 7th annual meeting of the working party ‘Biotransformations’ German Society for Applied Microbiology (VAAM) at ETH Zürich October 9.–11., 2002. The Role of Arg- 90 in the Active Site of Bacillus subtilis Chorismate Mutase. ii Index Index ii Acknowledgments vi Abstract viii Zusammenfassung xi 1 Introduction 1 1.1 Claisen Rearrangement 1 1.2 Shikimate Pathway 3 1.3 Chorismate Mutase 5 1.4 Active Sites of Chorismate Mutases 8 1.5 The Catalytic Mechanism of Chorismate Mutases 12 1.6 Goals of this Work 17 2 Site-specific Replacement of a Crucial Arginine in BsCM with an Isosteric but Uncharged Citrulline 18 2.1 Introduction 18 2.2 Introduction of Unnatural Amino Acids into Proteins 19 Stop Codon Suppression 19 Peptide Synthesis 21 Peptide Ligation 24 Inteins 27 Strategy for Preparing BsCM Variants with non-standard Amino Acids at Position 90 29 2.3 Results 30 2.4 Discussion 37 3 BsCM Variants Containing homo-Lysine or Difluoro-Arginine at Position 90 in the Active Site 41 3.1 Introduction 41 3.2 Results 43 Arg90homo-Lys BsCM* 43 Arg90F2Arg BsCM* 46 3.3 Discussion 58 iii 4 Investigation of Ligand Binding and Protein Dynamics in BsCM by TROSY-NMR 62 4.1 Introduction 62 4.2 Results 64 Assignment of backbone resonances 64 Ligand binding 68 15 N T1, T2, and HNOE Data 68 Model-Free Analysis of Intramolecular Backbone Mobility 72 4.3 Discussion 74 5 Outlook 81 6 Experimental Section 83 6.1 General 83 Abbreviations 83 Analytical Data 86 Solutions, Buffers, and Media Molecular Biology 96 Ingredients for Minimal Media 99 Buffers for Purification of BsCM 1-87, Intein, CBD Fusion 100 Strains, Plasmids, and Oligonucleotides 101 General Methods: Molecular Biology 102 General Procedures: Molecular Biology 109 Chemicals and General Procedures: Chemistry 111 Computer Programs 113 6.2 Peptide Synthesis 114 Fmoc-BsCM(108-127) 35 114 BsCM(98-127) 36 115 D102E BsCM(88-127) 9 116 Arg90Cit D102E BsCM(88-127) 10 118 Arg90Cit BsCM(88-93) 37 119 BsCM(88-93) 11 120 Fmoc-D102E BsCM(92-127) 38 121 Arg90homo-Lys D102E BsCM(88-127) 12 123 Arg90F2Arg D102E BsCM(88-127) 31 124 6.3 Cloning and Expression 125 BsCM(1-87) encoded by pTYB1-BsCM87 125 BsCM(1-87) encoded by pTXB1-BsCM87 126 D102E BsCM encoded by pAK-D102E 127 R105K BsCM encoded by pAK-R105K 128 D102E R105K BsCM encoded by pAK-DERK 129 BsCM(1-124) encoded by pAK-T125* 130 BsCM(1-122) encoded by pAK-K123* 131 BsCM(1-121) encoded by pAK-T122* 132 BsCM(1-120) encoded by pAK-L121* 133 iv BsCM(1-119) encoded by pAK-S120* 134 6.4 Native Chemical Ligation 135 D102E BsCM 135 Arg90Cit D102E BsCM 135 Arg90homo-Lys D102E BsCM 136 Arg90F2Arg D102E BsCM 137 6.5 Isotopically Labeled BsCM 137 15N-labeled BsCM 137 D (< 35%), 13C-, and 15N-labeled BsCM 138 D, 13C-, and 15N-labeled BsCM 139 D (50%), 13C-, and 15N-labeled BsCM 140 6.6 Synthesis of Fmoc-4,4-difluoro-L-arginine(Pbf)-OH 141 Synthesis of tert-butyl (4R)-4-(3-ethoxy-2,2-difluoro-1-hydroxy-3-oxopropyl)-2,2- dimethyl-1,3-oxazolane-3-carboxylate 18: 141 Synthesis of tert-butyl (4R)-4-3-ethoxy-2,2-difluoro-1-[(1H-imidazol-1- ylcarbothioyl)oxy]-3-oxopropyl-2,2-dimethyl-1,3-oxazolane-3-carboxylate 19: 143 Synthesis of tert-butyl (4S)-4-(3-ethoxy-2,2-difluoro-3-oxopropyl)-2,2-dimethyl- 1,3-oxazolane-3-carboxylate 20: 145 Synthesis of tert-butyl (4S)-4-(3-amino-2,2-difluoro-3-oxopropyl)-2,2-dimethyl- 1,3-oxazolane-3-carboxylate 21: 147 Synthesis of tert-butyl (4S)-4-(3-amino-2,2-difluoropropyl)-2,2-dimethyl-1,3- oxazolane-3-carboxylate 22: 148 Synthesis of tert-butyl (4S)-4-(3-[(benzyloxy)carbonyl]amino-2,2-difluoropropyl)- 2,2-dimethyl-1,3-oxazolane-3-carboxylate 23: 149 Synthesis of benzyl N-(4S)-4-[(tert-butoxycarbonyl)amino]-2,2-difluoro-5- hydroxypentylcarbamate 24: 151 Synthesis of tert-butyl N-[(1S)-4-amino-3,3-difluoro-1-(hydroxymethyl) butyl]carbamate 25: 152 Synthesis of tert-butyl N-[(Z)-[(tert-butoxycarbonyl)amino]((4S)-4-[(tert- butoxycarbonyl)amino]-2,2-difluoro-5-hydroxypentylamino) methylidene]carbamate 26: 153 Synthesis of (2S)-2-[(tert-butoxycarbonyl)amino]-5-([(tert- butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methylamino)-4,4- difluoropentanoic acid 27: 155 Synthesis of (2S)-2-amino-5-[amino(imino)methyl]amino-4,4-difluoropentanoic acid 8: 156 Synthesis of (2S)-5-[amino(imino)methyl]amino-2-[(benzyloxy)carbonyl]amino- 4,4-difluoropentanoic acid 28: 157 Synthesis of (2S)-2-[(benzyloxy)carbonyl]amino-4,4-difluoro-5-[(imino[(2,2,4,6,7- pentamethyl-2,3-dihydro-1-benzofuran-5- yl)sulfonyl]aminomethyl)amino]pentanoic acid 29: 158 Synthesis of (2S)-2-amino-4,4-difluoro-5-[(imino[(2,2,4,6,7-pentamethyl-2,3- dihydro-1-benzofuran-5-yl)sulfonyl] aminomethyl)amino]pentanoic acid 30: 160 Synthesis of (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino-4,4-difluoro-5- [(imino[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5- yl)sulfonyl]aminomethyl)amino]pentanoic acid 13: 161 v 7 Appendix 164 7.1 Programs for the Peptide Synthesizer 164 Modifications to the standard programs 164 7.2 Analytical Ultracentrifugation Data for BsCM* and Arg90Cit BsCM* 174 Data for BsCM* 174 Data for Arg90Cit BsCM* 175 8 Literature 177 vi Acknowledgments I would like to thank my “Doktorvater” Prof. Donald Hilvert for giving me the opportunity to work in his laboratory on this exciting and challenging project. His constant support, scientific enthusiasm and the granted freedom were essential for the success of this work. I also want to thank him for thoroughly proof-reading my thesis. Prof. Dario Neri I want to thank for being my co-examiner. I would like to thank my labmates from D32 and F328 for the enjoyable working atmosphere. I am in dept to Richard Quaderer and Axel Sewing for introducing me to peptide chemistry and HPLC and to the Praktikum 2000 and Andrea Piatesi for the introduction to molecular biology. It was always fun to solve different computer problems together with Andreas Aemissegger. The many happy hours we spent inside the lab and on various parties will always be lasting memories. Dr. Ajay Mandal was not only always willing to discuss chemistry problems but he also new all the good places for out of lab activities. Andreas Kleeb was always a good partner to discuss biology issues and he organized some unforgettable group events. I would like to thank Dr. Peter Kast for a lot of fruitful discussions about molecular biology problems.
Load more

Recommended publications
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Exploring the Chemistry and Evolution of the Isomerases
    Exploring the chemistry and evolution of the isomerases Sergio Martínez Cuestaa, Syed Asad Rahmana, and Janet M. Thorntona,1 aEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom Edited by Gregory A. Petsko, Weill Cornell Medical College, New York, NY, and approved January 12, 2016 (received for review May 14, 2015) Isomerization reactions are fundamental in biology, and isomers identifier serves as a bridge between biochemical data and ge- usually differ in their biological role and pharmacological effects. nomic sequences allowing the assignment of enzymatic activity to In this study, we have cataloged the isomerization reactions known genes and proteins in the functional annotation of genomes. to occur in biology using a combination of manual and computa- Isomerases represent one of the six EC classes and are subdivided tional approaches. This method provides a robust basis for compar- into six subclasses, 17 sub-subclasses, and 245 EC numbers cor- A ison and clustering of the reactions into classes. Comparing our responding to around 300 biochemical reactions (Fig. 1 ). results with the Enzyme Commission (EC) classification, the standard Although the catalytic mechanisms of isomerases have already approach to represent enzyme function on the basis of the overall been partially investigated (3, 12, 13), with the flood of new data, an integrated overview of the chemistry of isomerization in bi- chemistry of the catalyzed reaction, expands our understanding of ology is timely. This study combines manual examination of the the biochemistry of isomerization. The grouping of reactions in- chemistry and structures of isomerases with recent developments volving stereoisomerism is straightforward with two distinct types cis-trans in the automatic search and comparison of reactions.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • Medications in Pregnant and Nursing Mothers
    Medications in Pregnant and Nursing Mothers NADINE M. GIRGIS, OD, FAAO ASSISTANT PROFESSOR YIN C. TEA, OD, FAAO CHIEF, PEDIATRICS AND BINOCULAR VISION ASSISTANT PROFESSOR Gestation age vs fetal age Gestation age-sperm penetrates the egg and zygote is formed Zygote (fertilized egg) travels from fallopian tube to uterus During this time, egg divides into cells - called a morula Continued dividing and morula - called a blastocyst - embeds in the uterus anywhere from 6-12 days after conception This begins the embryonic stage and fetal age begins Fetal development-1st trimester Gestation age week 3-fetal age week 1: a lot of basic growth Brain, spinal cord, heart, GI tract begin development 1st trimester Gestation age-week 4 and 5: embryo ¼ inch long Arm and leg buds, ears, eyes forming Placenta forming and producing hormones Heart is beating at a steady rhythm Movement of rudimentary blood through blood vessels 1st trimester Gestation age week 6: embryo is ½ in length Lungs, jaw, nose, plate formation, hands and feet Hand and feet buds have webbed structures Brain forming into complex parts 1st trimester Gestation age week 7: weighs less than an aspirin All essential organs have begun to form Hair, nail follicles, eyelids and tongue starting to form Trunk begins to straighten out 1st trimester Gestation age week 8: 1 in long, size of a bean All parts of adult are now present in the embryo Bones beginning to form Muscles begin to contract Facial features, including eyelids more developed Gestation age weeks 9-13: 3 in and weighs
    [Show full text]
  • Amino Acid Residue. Chorismate Mutase by Variation of a Single
    Modulation of the allosteric equilibrium of yeast chorismate mutase by variation of a single amino acid residue. R Graf, Y Dubaquié and G H Braus J. Bacteriol. 1995, 177(6):1645. Downloaded from Updated information and services can be found at: http://jb.asm.org/content/177/6/1645 These include: CONTENT ALERTS Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» http://jb.asm.org/ on March 22, 2013 by guest Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ JOURNAL OF BACTERIOLOGY, Mar. 1995, p. 1645–1648 Vol. 177, No. 6 0021-9193/95/$04.0010 Copyright q 1995, American Society for Microbiology Modulation of the Allosteric Equilibrium of Yeast Chorismate Mutase by Variation of a Single Amino Acid Residue RONEY GRAF,† YVES DUBAQUIE´,‡ AND GERHARD H. BRAUS* Institut fu¨r Mikrobiologie, Biochemie & Genetik, Friedrich-Alexander Universita¨t Erlangen-Nu¨rnberg, D-91058 Erlangen, Germany Received 26 September 1994/Accepted 11 January 1995 Chorismate mutase (EC 5.4.99.5) from the yeast Saccharomyces cerevisiae is an allosteric enzyme which can be locked in its active R (relaxed) state by a single threonine-to-isoleucine exchange at position 226. Seven new replacements of residue 226 reveal that this position is able to direct the enzyme’s allosteric equilibrium, without interfering with the catalytic constant or the affinity for the activator. Downloaded from Chorismate is the last common precursor of the amino acids amino acid 226 of yeast chorismate mutase to glycine and tyrosine, phenylalanine, and tryptophan and an important in- alanine (small), aspartate and arginine (charged), serine (hy- termediate in the biosynthesis of other aromatic compounds in drophilic, similar to the wild-type threonine), cysteine (sulfur fungi, bacteria, and plants (9).
    [Show full text]
  • Preferred Drug List
    October 2021 Preferred Drug List The Preferred Drug List, administered by CVS Caremark® on behalf of Siemens, is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • This drug list represents a summary of prescription coverage. It is this document. Products recently approved by the U.S. Food and not all-inclusive and does not guarantee coverage.
    [Show full text]
  • Specific Pattern of Gene Expression During Induction of Mouse Erythroleukemia Cells
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Specific pattern of gene expression during induction of mouse erythroleukemia cells Peter J. Fraser and Peter J. Curtis The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104 USA We have studied the expression of several characterized genes during induction of mouse erythroleukemia (MEL) cells with dimethyl sulfoxide (DMSO) and have observed a specific pattern of changes in transcriptional activity and steady-state RNA levels associated with erythroid differentiation. During induction there is a gradual, steady decrease in total transcriptional activity and RNA content per cell, which by day 3 of DMSO treatment amounts to less than 50% of the level in the uninduced cell. During this time we observe increases in transcriptional activity for 5-aminolevulinic acid synthase, carbonic anhydrase form II, and band 3 coordinate with the large increase in [3-globin gene transcription. The results also demonstrate an early decrease in transcription for carbonic anhydrase form I, which precedes decreases in transcription for glyceraldehyde phosphate dehydrogenase and rRNA genes. Changes in steady-state RNA levels reflected changes in transcriptional activity during induction except for carbonic anhydrase II mRNA. These results represent the first report characterizing the regulated expression at transcriptional and posttranscriptional levels of several known genes that are characteristically expressed in the erythrocyte. The results demonstrate that coordinate gene expression in erythroid differentiation occurs primarily at the level of transcription. [Key Words: Coordinated gene regulation; transcriptional activity; erythroid differentiation] Received June 25, 1987; revised version accepted August 14, 1987. Adult erythroid differentiation requires activation and/ dinately such that they may assemble to form the char- or modulation of many genes whose expression is regu- acteristic erythrocyte cytoskeleton.
    [Show full text]
  • Table S1. the Bacterial and Fungal Isolates Used for the in Vitro Activity Testing
    Table S1. The bacterial and fungal isolates used for the in vitro activity testing. KTU-286 Microorganism Strain No Feature MIC (µg/mL) Acinetobacter baummanii ATCC 17978 Reference strain 128 < Aspergillus flavus 12B Clinical isolate 128 < Aspergillus fumigatus 14 Clinical isolate 128 < Candida albicans ATCC 10231 Type strain 128 < Candida auris CAU-1 Clinical isolate 128 < Cuninghamella corymbifera CC1 Clinical isolate 128 < Escherichia coli 10025 Mcr-1 128 Escherichia coli DH5a Pan-S 128 Klebsiella pneumoniae 3122 blaKPC 128 < Klebsiella pneumoniae 4141 blaNDM-1 128 < Mycobacterium abscesus IP-K01 Clinical isolate 64 Mycobacterium bovis BCG Type strain 128 < Mycobacterium smegmatis mc2155 Type strain 128 < Pseudomonas aeruginosa 3691 AmpC 128 < Pseudomonas aeruginosa 3656 Pan-S 128 < Pseudomonas aeruginosa 3647 Efflux pump overexpression 128 < Pseudomonas aeruginosa 3619 OPRD 128 < Staphylococcus aureus 875 MRSA 1 Table S2. The In silico predictions of human proteins interacting with KTU-286. The in silico predictions were computed using SwissTargetPrediction tool. Common Uniprot ChEMBL Probab Identified target Target Class name ID ID ility CHEMBL2 0.10057 Arachidonate 5-lipoxygenase ALOX5 P09917 Oxidoreductase 15 8902 CHEMBL5 0.10057 Prostaglandin E synthase PTGES O14684 Enzyme 658 8902 CHEMBL2 Family A G protein- 0.10057 Interleukin-8 receptor B CXCR2 P25025 434 coupled receptor 8902 CHEMBL2 0.10057 Cyclooxygenase-2 PTGS2 P35354 Oxidoreductase 30 8902 CHEMBL3 0.10057 Carboxylesterase 2 CES2 O00748 Enzyme 180 8902 CHEMBL5 0.10057 Poly
    [Show full text]
  • Targeting Mycobacterium Tuberculosis Proteins: Structure and Function Studies of Five Essential Proteins
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 411 Targeting Mycobacterium tuberculosis Proteins: Structure and Function Studies of Five Essential Proteins ADRIAN SUAREZ COVARRUBIAS ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 UPPSALA ISBN 978-91-554-7134-7 2008 urn:nbn:se:uu:diva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ist of publications This thesis consists of a comprehensive summary based on the following papers. In the text, the papers will be referred to by their roman numerals. I Covarrubias, A. S., Larsson, A. M., Högbom, M., Lindberg, J., Bergfors, T., Björkelid, C., Mowbray, S. L., Unge, T., and Jones, T. A. (2005). Structure and
    [Show full text]
  • O O2 Enzymes Available from Sigma Enzymes Available from Sigma
    COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc.
    [Show full text]
  • Syntheses of Chorismate Analogs for Investigation of Structural Requirements for Chorismate Mutase
    Syntheses of Chorismate Analogs for Investigation of Structural Requirements for Chorismate Mutase by Chang-Chung Cheng B.S., Department of Chemistry National Chung-Hsing University 1986 Submitted to the Department of Chemistry in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Organic Chemistry at the Massachusetts Institute of Technology May, 1994 © 1994 Chang-Chung Cheng All rights reserved The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in oart. Signature of Author... ............ ............ ......................................................... Department of Chemistry May 18, 1994 Certified by...................................... Glenn A. Berchtold Thesis Supervisor Accepted by..........................................-. ,..... ......................................................... Glenn A. Berchtold Science Chairman, Departmental Committee on Graduate Studies JUN 2 1 1994 LjENrVUVk*_ This doctoral thesis has been examined by a Committee of the Department of Chemistry as Follows: Professor Frederick D. Greene, II......... .......... Chairman Professor Glenn A. Berchtold .ThS................................ Thesis Supervisor Professor Julius Rebek, Jr............... .. ............................................L% 1 Foreword Chang-Chung (Cliff) Cheng's Ph. D. thesis is a special thesis for me because of our association with the individual who supervised his undergraduate research and since Cliff will be the last student to receive the Ph. D. from me during my career at M.I.T.. Cliff received the B.S. degree in Chemistry from National Chung-Hsing University, Taichung, Taiwan in June 1986, and he enrolled in our doctoral program in September 1989. During his undergraduate career Cliff was engaged in research under the supervision of Professor Teng-Kuei Yang. Professor Yang also received his undergraduate training in chemistry at National Chung-Hsing University before coming to the United States to complete the Ph.
    [Show full text]
  • Building Microbial Factories for The
    Contents lists available at ScienceDirect Metabolic Engineering journal homepage: www.elsevier.com/locate/meteng Building microbial factories for the production of aromatic amino acid pathway derivatives: From commodity chemicals to plant-sourced natural products ∗ Mingfeng Caoa,b,1, Meirong Gaoa,b,1, Miguel Suásteguia,b, Yanzhen Meie, Zengyi Shaoa,b,c,d, a Department of Chemical and Biological Engineering, Iowa State University, USA b NSF Engineering Research Center for Biorenewable Chemicals (CBiRC), Iowa State University, USA c Interdepartmental Microbiology Program, Iowa State University, USA d The Ames Laboratory, USA e School of Life Sciences, No.1 Wenyuan Road, Nanjing Normal University, Qixia District, Nanjing, 210023, China ARTICLE INFO ABSTRACT Keywords: The aromatic amino acid biosynthesis pathway, together with its downstream branches, represents one of the Aromatic amino acid biosynthesis most commercially valuable biosynthetic pathways, producing a diverse range of complex molecules with many Shikimate pathway useful bioactive properties. Aromatic compounds are crucial components for major commercial segments, from De novo biosynthesis polymers to foods, nutraceuticals, and pharmaceuticals, and the demand for such products has been projected to Microbial production continue to increase at national and global levels. Compared to direct plant extraction and chemical synthesis, Flavonoids microbial production holds promise not only for much shorter cultivation periods and robustly higher yields, but Stilbenoids Benzylisoquinoline alkaloids also for enabling further derivatization to improve compound efficacy by tailoring new enzymatic steps. This review summarizes the biosynthetic pathways for a large repertoire of commercially valuable products that are derived from the aromatic amino acid biosynthesis pathway, and it highlights both generic strategies and spe- cific solutions to overcome certain unique problems to enhance the productivities of microbial hosts.
    [Show full text]